Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice-Reference-Cited by-同舟云学术

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Published:2024-04 Issue:2 Volume:11 Page:57-61
ISSN:2311-3006
Container-title:Journal of Cancer Research and Practice
language:en
Short-container-title:

Author:

Cheng Mei-Fang¹²,Yen Chih-Chieh³,Du Jeng-Shiun⁴,Chiu Yu-Li⁵,Chen Ming-Huang⁶⁷,Tsai Hui-Jen³⁴⁸,Wu I-Chen⁴,Shen Hueng-Yuan⁵,Yen Ruoh-Fang¹,Chen Li-Tzong³⁴⁸,

Affiliation:

1. Department of Nuclear Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan

2. Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan

3. Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4. Department of Internal Medicine, Kaohsiung Medical University Hospital, and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan

5. Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

6. Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

7. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

8. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Abstract

Abstract Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT). Data Sources and Study Selection: We searched various scientific databases using specific keywords. Results: Due to the overexpression of somatostatin receptors in neuroendocrine tumors (NETs), PRRT is currently considered an important therapeutic modality for the management of NETs. Conclusion: PRRT incorporates the systemic administration of a tumor-targeting radiolabeled peptide to patients with tumors, allowing for more precise delivery of radiation doses to tumor sites while sparing normal tissues.

Publisher

Medknow

Reference31 articles.

1. Paul Ehrlich's magic bullet concept:100 years of progress;Strebhardt;Nat Rev Cancer,2008

2. Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine;Valent;J Innate Immun,2016

3. Targeted radionuclide therapy:An emerging field in solid tumours;Artigas;Curr Opin Oncol,2021

4. Auger electrons for cancer therapy –A review;Ku;EJNMMI Radiopharm Chem,2019

5. New Developments in Peptide Receptor Radionuclide Therapy;Nicolas;J Nucl Med,2019